Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease

Journal of Clinical Investigation

Volumn 97, Issue 5, 1996, Pages 1227-1234

  Brugnara, Carlo ^a   Gee, Beatrice ^a   Armsby, Carrie C ^a   Kurth, Susan ^a   Sakamoto, Masayuki ^a   Rifai, Nader ^a   Alper, Seth L ^b   Platt, Orah S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

antisickling agents; clotrimazole; erythrocyte; imidazoles; K channel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLOTRIMAZOLE; HEMOGLOBIN S; IMIDAZOLE DERIVATIVE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM ION;

ADOLESCENT; ADULT; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG MECHANISM; DYSURIA; ERYTHROCYTE; HEMOLYSIS; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SICKLE CELL ANEMIA; VOMITING; WATER CONTENT;

EID: 0029865706     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118537     Document Type: Article

References (40)

1. Hebbel, R.P. 1991. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 77.214-237.
2. Eaton, W.A., and J. Hofrichter. 1987. Hemoglobin S gelation and sickle cell disease. Blood. 70:1245-1266.
3. Platt, O S , S.H. Orkin, G. Dover, G.P. Beardsley, B. Miller, and D.G. Nathan. 1984. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin. Invest. 74.652-656.
4. Goldberg, M.A , C. Brugnara, G.J. Dover, L. Shapira, S. Charache, and H.F. Bunn. 1990 Treatment of sickle cell anemia with hydroxyurea and erythropoietin N. Engl. J Med. 323:366-372.
5. Rodgers, G.P , G.J. Dover, N. Uyesaka, C.T. Noguchi, A.N. Schechter, and A.W. Nienhuis 1993. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N. Engl. J. Med 328:73-80.
6. Charache, S., G.J Dover, R.D. Moore, S. Eckert, S.K. Ballas, M. Koshy, P.F.A. Milner, E.P. Orringer, G. Phillips, Jr , O.S. Platt, and G.H. Thomas. 1992. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 79:2555-2565.
7. Rosa, R.M., B.E. Bierer, R. Thomas, J.S. Stoff, M. Kruskall, S. Robinson, H.F. Bunn, and F H. Epstein. 1980. A study of induced hyponatremia in the prevention and treatment of sickle cell crisis. N. Engl. J. Med 303:1138-1143.
8. Charache, S , and W.O. Walker. 1981. Failure of desmopressin to lower serum sodium or prevent crisis in patients with sickle cell anemia. Blood. 58. 892-896.
9. Brugnara, C , H.F. Bunn, and D.C. Tosteson. 1986. Regulation of erythrocyte cation and water content in sickle cell anemia Science (Wash DC). 232: 388-390.
10. - transport is elevated in SS, SC and CC human red cells. FEBS Lett. 200:197-202.
11. Brugnara, C., T. Van Ha, and D.C. Tosteson. 1989. Acid pH induces formation of dense cells in sickle erythrocytes. Blood. 74:487-495.
12. Gardos, G. 1958. The function of calcium in the potassium permeability of human erythrocytes Biochim. Biophys. Acta. 30.653-654.
13. Glader, B.E., and D.G. Nathan. 1978. Cation permeability alterations during sickling: relationship to cation composition and cellular hydration of irreversibly sickled cells Blood. 51:983-989.
14. Bookchin, R.M., O.E. Ortiz, and V.L. Lew. 1991. Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J. Clin Invest. 87: 113-124.
15. - transport of human and rabbit erythrocytes: comparison of binding and transport inhibition by scorpion toxins. J. Biol. Chem 268:8760-8768.
16. Berkowitz, L.R., and P. Orringer. 1981. Effect of cetiedil, an in vitro anti-sickling agent, on erythrocyte membrane cation permeability. J. Clin. Invest. 68.1215-1220.
17. Benjamin, L.J., L.R Berkowitz, E.P. Orringer, V.N. Mankad, A.S. Prasad, L.M. Lewkow, R.K. Chillar, and C.M. Peterson. 1986. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crises. Blood. 67: 1442-1447.
18. + channels by cytochrome P-450 inhibitors. J. Biol. Chem. 267:11789-11793.
19. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin. Invest. 92:520-526.
20. + current in several cell types. J. Gen. Physiol. 104:15a-16a.
21. + transport and reverses erythrocyte dehydration in transgenic SAD mice A model for therapy of sickle cell disease J. Clin. Invest. 93:1670-1676.
22. + channel: the imidazole ring is not required for inhibitory activity J. Pharmacol Exp. Ther. 273:266-272
23. Lew, V.L., C.J. Freeman, O.E. Ortiz, and R.M. Bookchin. 1991 A mathematical model of the volume, pH and ion content regulation in reticulocytes. J. Clin. Invest. 87:100-112.
24. Rifai, N., M. Sakamoto, T. Law, O. Platt, M Mikati, C.C. Armsby, and C. Brugnara. 1995. Measurement by HPLC, blood distribution and pharmacokinetics of oral clotrimazole, a new potential antisickling agent. Clin Chem 41: 387-391.
25. Brugnara, C., M.J. Hipp, P.J. Irving, H. Lathrop, P.A. Lee, E.M. Minchello, and J. Winkelman. 1994. Automated reticulocyte counting and measurement of reticulocyte cellular indices: evaluation of the Miles H*3 blood analyzer. Am. J. Clin. Pathol. 102:623-632.
26. Seo, M., H. Iida, and Y. Miura. 1977. Basic experiments with clotrimazole administered orally. Curr. Med. Res. Opin. 5:169-178.
27. Weuta, H. 1974. Clinical studies with oral clotrimazole. Postgrad. Med. J. 50(Suppl. 1):45-49.
28. Duhm, B., W Maul, H. Medenwald, K. Patzschke, J. Puetter, and L.A. Wegner. 1974. The pharmacokinetics of clotrimazole 14C. Postgrad. Med. J. 50(Suppl. 1):13-16.
29. Sawyer, P.R., R.N. Brogden, R.M. Pinder, T.M. Speight, and G.S. Avery. 1975. Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 9:424-447.
30. Matsuura, Y., E. Kotani, T. Iio, T. Fukuda, S. Tobinaga, T. Yoshida, and Y. Kuroiwa. 1991. Structure-activity relationship in the induction of hepatic microsomal cytochrome P450 by clotrimazole and its structurally related compounds in rats. Biochem. Pharmacol. 41:1949-1956.
31. Ortiz, O.E., V.L. Lew, and R.M. Bookchin 1990. Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells. J. Physiol. 427:211-226.
32. Danon, D., and Y. Marikovsky. 1964. Determination of density distribution of red cell population. J. Lab. Clin. Med. 64:668-674.
33. Fabry, M., J.R. Romero, I.D. Buchanan, S.M. Suzuka, G. Stamatoyannopoulos, R.L. Nagel, and M. Canessa. 1991. Rapid increase in red blood cell density driven by the K-Cl cotransport in a subset of sickle cell anemia reticulocytes and discocytes. Blood. 78:217-225.
34. Franco, R.S., M. Palascak, H. Thompson, and C.H. Joiner. 1995. KCl cotransport activity in light versus dense transferrin receptor-positive sickle erythrocytes. J. Clin. Invest. 95:2573-2580.
35. ++ entry into GH3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers. FASEB (Fed. Am. Soc. Exp. Biol.) J. 6:2742-2747.
36. 2+ permeability in deoxygenated sickle cells. Blood. 75:2453-2458.
37. Benzaquen, L., C. Brugnara, H.R. Byers, S. Gattoni-Celli, and J.A. Halperm. 1995. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nature Med. 1:534-540.
38. Tranquille, N., and J.J. Emeis. 1992. The involvement of products of the phospholipase pathway in the acute release of tissue-type plasminogen activator from perfused rat hindlegs. Eur. J. Pharmacol. 213:285-292.
39. Wick, T.M., J.L. Moake, M.M. Udden, S.G. Eskin, D.A. Sears, and L.V. McIntire. 1987. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J. Clin. Invest. 80:905-910.
40. De Franceschi, L., P. Rouyer-Fessard, S.L. Alper, H. Jouault, C. Brugnara, and Y. Beuzard. 1996. Combination therapy of erythropoietin, hydroxyurea, and ciotrimazole in a β thalassemic mouse: a model for human therapy. Blood 87:1188-1195.